MedDay's MD1003 decreases disease progression in patients with progressive MS

Privately held French biotechnology firm MedDay has announced positive results from the pivotal Phase III clinical trial, MS-SPI, with its multiple sclerosis drug candidate MD1003, at the annual meeting of the American Academy of Neurology.

The study demonstrated evidence of the efficacy and safety of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300mg per day in the treatment of primary and secondary progressive multiple sclerosis, a major area of unmet medical need.

“This is the first time that a drug has been able to decrease the rate of disease progression in addition to improving a significant proportion of patients with progressive MS,” said MedDay chief executive Frederic Sedel.